Related Experiment Videos
[Therapy of systemic mycoses in immunodeficiency]
1Zentrum für Innere Medizin, Universität Frankfurt/Main.
Immunitat Und Infektion
|August 1, 1991
Summary
Systemic fungal infections are rising due to increased immunodeficiency. Treatment varies by pathogen, with fluconazole for mild Candida, amphotericin B plus flucytosine for severe cases, and azoles for mild Aspergillus infections.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Immunocompromised Host
Context:
- Increasing incidence of invasive fungal infections.
- Growing population of immunocompromised patients.
- Limited systemic antifungal agents available.
Purpose:
- To review current treatment strategies for common opportunistic fungal infections.
- To highlight the importance of early diagnosis and appropriate therapy.
- To discuss the role of specific antifungal agents against Candida, Aspergillus, and Cryptococcus.
Summary:
- Candida albicans infections: fluconazole for mild, amphotericin B plus flucytosine for severe.
- Aspergillus fumigatus infections: amphotericin B plus flucytosine as first choice, itraconazole for mild cases.
- Cryptococcus neoformans infections (meningitis): combination therapy with amphotericin B, flucytosine, and fluconazole, followed by long-term fluconazole.
Impact:
- Guides clinical decision-making for managing invasive fungal infections.
- Emphasizes the need for prompt treatment in immunocompromised patients.
- Informs the development of new antifungal therapies and treatment protocols.